Rajiv Kumar

List of Publications by Year in Descending Order

238 papers	13,271 citations	59 h-index	108 g-index
251 ext. papers	14,993 ext. citations	6.8 avg, IF	5.78 L-index

#	Paper	IF	Citations
238	Mutational Characterization of Cutaneous Melanoma Supports Divergent Pathways Model for Melanoma Development. *Cancers*, **2021**, 13,	6.6	1
237	Longitudinal study of prognostic factors for localized cutaneous melanoma in patients who have been disease-free for five years. *European Journal of Dermatology*, **2021**, 31, 192-198	0.8	1
236	Clinical, environmental and histological distribution of BRAF, NRAS and TERT promoter mutations among patients with cutaneous melanoma: a retrospective study of 563 patients. *British Journal of Dermatology*, **2021**, 184, 504-513	4	9
235	Polymorphisms in CXCR3 ligands predict early CXCL9 recovery and severe chronic GVHD. *Blood Cancer Journal*, **2021**, 11, 42	7	1
234	KIT mutational status does not constitute an independent prognostic marker in cutaneous melanoma. A study on 688 Spanish patients. *Melanoma Research*, **2021**, 31, 101-103	3.3	
233	Occurrence, functionality and abundance of the TERT promoter mutations. *International Journal of Cancer*, **2021**, 149, 1852-1862	7.5	2
232	Association of HERV-K and LINE-1 hypomethylation with reduced disease-free survival in melanoma patients. *Epigenomics*, **2020**, 12, 1689-1706	4.4	4
231	Telomerase Reverse Transcriptase Promoter Mutations Identify a Genomically Defined and Highly Aggressive Human Pleural Mesothelioma Subgroup. *Clinical Cancer Research*, **2020**, 26, 3819-3830	12.9	8
230	Mutation Signatures in Melanocytic Nevi Reveal Characteristics of Defective DNA Repair. *Journal of Investigative Dermatology*, **2020**, 140, 2093-2096.e2	4.3	2
229	Risk factors for the development of a second melanoma in patients with cutaneous melanoma. *Journal of the European Academy of Dermatology and Venereology*, **2020**, 34, 2295-2302	4.6	7
228	Telomeres and Telomere Length: A General Overview. *Cancers*, **2020**, 12,	6.6	56
227	Assessment of polygenic architecture and risk prediction based on common variants across fourteen cancers. *Nature Communications*, **2020**, 11, 3353	17.4	32
226	TERT promoter mutations in actinic keratosis before and after treatment. *International Journal of Cancer*, **2020**, 146, 2932-2934	7.5	1
225	Genome-wide characterization of 5-hydoxymethylcytosine in melanoma reveals major differences with nevus. *Genes Chromosomes and Cancer*, **2020**, 59, 366-374	5	3
224	Genome-wide association meta-analyses combining multiple risk phenotypes provide insights into the genetic architecture of cutaneous melanoma susceptibility. *Nature Genetics*, **2020**, 52, 494-504	36.3	39
223	Chromosomal damage and telomere length in peripheral blood lymphocytes of cancer patients. *Oncology Reports*, **2020**, 44, 2219-2230	3.5	0
222	Coding and noncoding somatic mutations in candidate genes in basal cell carcinoma. *Scientific Reports*, **2020**, 10, 8005	4.9	13

221	Telomere length in peripheral blood lymphocytes related to genetic variation in telomerase, prognosis and clinicopathological features in breast cancer patients. *Mutagenesis*, **2020**, 35, 491-497	2.8	2
220	Expression quantitative trait loci in ABC transporters are associated with survival in 5-FU treated colorectal cancer patients. *Mutagenesis*, **2020**, 35, 273-281	2.8	1
219	Informing patients about their mutation tests: CDKN2A c.256G>A in melanoma as an example. *Hereditary Cancer in Clinical Practice*, **2020**, 18, 15	2.3	0
218	MC1R variants and cutaneous melanoma risk according to histological type, body site, and Breslow thickness: a pooled analysis from the M-SKIP project. *Melanoma Research*, **2020**, 30, 500-510	3.3	2
217	Lymphatic and Hematogenous Dissemination in Patients With Primary Cutaneous Melanoma-Reply. *JAMA Dermatology*, **2019**, 155, 1323	5.1	
216	Risk Factors for Lymphatic and Hematogenous Dissemination in Patients With Stages I to II Cutaneous Melanoma. *JAMA Dermatology*, **2019**, 155, 679-687	5.1	13
215	Telomere length, arsenic exposure and risk of basal cell carcinoma of skin. *Carcinogenesis*, **2019**, 40, 715-723	4.2	10
214	MC1R variants in childhood and adolescent melanoma: a retrospective pooled analysis of a multicentre cohort. *The Lancet Child and Adolescent Health*, **2019**, 3, 332-342	14.5	8
213	Promoter Mutations are Associated with Visceral Spreading in Melanoma of the Trunk. *Cancers*, **2019**, 11,	6.6	11
212	TERT promoter mutation subtypes and survival in stage I and II melanoma patients. *International Journal of Cancer*, **2019**, 144, 1027-1036	7.5	27
211	TERT expression is susceptible to BRAF and ETS-factor inhibition in BRAF/TERT promoter double-mutated glioma. *Acta Neuropathologica Communications*, **2019**, 7, 128	7.3	18
210	Relationship of telomere length in colorectal cancer patients with cancer phenotype and patient prognosis. *British Journal of Cancer*, **2019**, 121, 344-350	8.7	14
209	The CXCL9 Polymorphism rs884304 Associates with Early CXCL9 Reconstitution and with Severe Chronic Graft-Versus-Host Disease (cGVHD) in Human Allograft Recipients. *Blood*, **2019**, 134, 873-873	2.2	
208	TERT promoter mutation subtypes in 20 in-situ melanomas. *Melanoma Research*, **2019**, 29, 347-348	3.3	
207	Asymmetric dimethylarginine serum levels are associated with early mortality after allogeneic stem cell transplantation. *Haematologica*, **2019**, 104, 827-834	6.6	3
206	Genome-wide association study identifies susceptibility loci for B-cell childhood acute lymphoblastic leukemia. *Nature Communications*, **2018**, 9, 1340	17.4	39
205	Bleomycin-induced chromosomal damage and shortening of telomeres in peripheral blood lymphocytes of incident cancer patients. *Genes Chromosomes and Cancer*, **2018**, 57, 61-69	5	10
204	Characteristics of Familial Melanoma in Valencia, Spain, Based on the Presence of CDKN2A Mutations and MC1R Variants. *Acta Dermato-Venereologica*, **2018**, 98, 512-516	2.2	

203	TERT promoter mutations are associated with poor prognosis and cell immortalization in meningioma. *Neuro-Oncology*, **2018**, 20, 1584-1593	1	58
202	Telomere length and survival in primary cutaneous melanoma patients. *Scientific Reports*, **2018**, 8, 10947	4.9	11
201	Leukocyte telomere length throughout the continuum of colorectal carcinogenesis. *Oncotarget*, **2018**, 9, 13582-13592	3.3	4
200	Genetic Risk of Severe Chronic Graft-Versus-Host Disease Defined By Host-Derived CXCR3 Ligands. *Blood*, **2018**, 132, 357-357	2.2	
199	Single Nucleotide Polymorphisms in CD40L Predict Endothelial Complications and Mortality After Allogeneic Stem-Cell Transplantation. *Journal of Clinical Oncology*, **2018**, 36, 789-800	2.2	14
198	Defective DNA damage repair leads to frequent catastrophic genomic events in murine and human tumors. *Nature Communications*, **2018**, 9, 4760	17.4	37
197	P02.10 Aggressiveness of meningiomas is predicted by cell immortalization in vitro and dependent on TERT promoter mutations. *Neuro-Oncology*, **2018**, 20, iii274-iii274	1	78
196	Telomere length, telomerase reverse transcriptase promoter mutations, and melanoma risk. *Genes Chromosomes and Cancer*, **2018**, 57, 564-572	5	24
195	Altered TERT promoter and other genomic regulatory elements: occurrence and impact. *International Journal of Cancer*, **2017**, 141, 867-876	7.5	14
194	TERT promoter mutations in telomere biology. *Mutation Research - Reviews in Mutation Research*, **2017**, 771, 15-31	7	93
193	TERT promoter mutations associate with MC1R variants in melanoma patients. *Pigment Cell and Melanoma Research*, **2017**, 30, 273-275	4.5	7
192	Distribution of TERT promoter mutations in primary and metastatic melanomas in Austrian patients. *Journal of Cancer Research and Clinical Oncology*, **2017**, 143, 613-617	4.9	12
191	TERT promoter mutations are not always associated with poor prognosis in atypical spitzoid tumors. *Pigment Cell and Melanoma Research*, **2017**, 30, 265-268	4.5	9
190	Genetic alterations in seborrheic keratoses. *Oncotarget*, **2017**, 8, 36639-36649	3.3	28
189	New prognostic factor telomerase reverse transcriptase promotor mutation presents without MR imaging biomarkers in primary glioblastoma. *Neuroradiology*, **2017**, 59, 1223-1231	3.2	9
188	A genome-wide association study identifies risk loci for childhood acute lymphoblastic leukemia at 10q26.13 and 12q23.1. *Leukemia*, **2017**, 31, 573-579	10.7	52
187	Cutaneous melanoma primary site is linked to nevus density. *Oncotarget*, **2017**, 8, 98876-98886	3.3	5
186	ETS1, nucleolar and non-nucleolar TERT expression in nevus to melanoma progression. *Oncotarget*, **2017**, 8, 104408-104417	3.3	6

185	Association of Melanocortin-1 Receptor Variants with Pigmentary Traits in Humans: A Pooled Analysis from the M-Skip Project. *Journal of Investigative Dermatology*, **2016**, 136, 1914-1917	4.3	12
184	Identification of a novel susceptibility locus at 13q34 and refinement of the 20p12.2 region as a multi-signal locus associated with bladder cancer risk in individuals of European ancestry. *Human Molecular Genetics*, **2016**, 25, 1203-14	5.6	20
183	PARKIN Inactivation Links Parkinson's Disease to Melanoma. *Journal of the National Cancer Institute* , **2016**, 108,	9.7	46
182	Characterization of individuals at high risk of developing melanoma in Latin America: bases for genetic counseling in melanoma. *Genetics in Medicine*, **2016**, 18, 727-36	8.1	18
181	Risk factors for keratinocyte skin cancer in patients diagnosed with melanoma, a large retrospective study. *European Journal of Cancer*, **2016**, 53, 115-24	7.5	10
180	Mapping of deletion breakpoints at the CDKN2A locus in melanoma: detection of MTAP-ANRIL fusion transcripts. *Oncotarget*, **2016**, 7, 16490-504	3.3	18
179	Thrombosis in a population of phase I trial patients.. *Journal of Clinical Oncology*, **2016**, 34, e14054-e14054	2.2	
178	MELADIAG: A panel of DNA biomarkers dedicated to melanoma diagnosis.. *Journal of Clinical Oncology*, **2016**, 34, e23258-e23258	2.2	
177	TERT promoter mutations in melanoma render TERT expression dependent on MAPK pathway activation. *Oncotarget*, **2016**, 7, 53127-53136	3.3	42
176	SERPINB1 expression is predictive for sensitivity and outcome of cisplatin-based chemotherapy in melanoma. *Oncotarget*, **2016**, 7, 10117-32	3.3	12
175	TERT promoter mutations associate with fast-growing melanoma. *Pigment Cell and Melanoma Research*, **2016**, 29, 236-8	4.5	32
174	TERT promoter mutations in melanoma survival. *International Journal of Cancer*, **2016**, 139, 75-84	7.5	79
173	Genome-wide meta-analysis identifies five new susceptibility loci for cutaneous malignant melanoma. *Nature Genetics*, **2015**, 47, 987-995	36.3	162
172	A novel c. 204 Ile68Met germline variant in exon 2 of the mutL homolog 1 gene in a colorectal cancer patient. *Oncology Letters*, **2015**, 9, 183-186	2.6	2
171	MC1R gene variants and non-melanoma skin cancer: a pooled-analysis from the M-SKIP project. *British Journal of Cancer*, **2015**, 113, 354-63	8.7	26
170	New basal cell carcinoma susceptibility loci. *Nature Communications*, **2015**, 6, 6825	17.4	49
169	Genes involved in the WNT and vesicular trafficking pathways are associated with melanoma predisposition. *International Journal of Cancer*, **2015**, 136, 2109-19	7.5	21
168	Telomere length in circulating lymphocytes: Association with chromosomal aberrations. *Genes Chromosomes and Cancer*, **2015**, 54, 194-6	5	11

167	TERT promoter mutations in clear cell renal cell carcinoma. *International Journal of Cancer*, **2015**, 136, 2448-52	7.5	36
166	TERT promoter mutations: a novel independent prognostic factor in primary glioblastomas. *Neuro-Oncology*, **2015**, 17, 45-52	1	123
165	MC1R variants increased the risk of sporadic cutaneous melanoma in darker-pigmented Caucasians: a pooled-analysis from the M-SKIP project. *International Journal of Cancer*, **2015**, 136, 618-31	7.5	67
164	Genetic variation in arsenic (+3 oxidation state) methyltransferase (AS3MT), arsenic metabolism and risk of basal cell carcinoma in a European population. *Environmental and Molecular Mutagenesis*, **2015**, 56, 60-9	3.2	40
163	The 9p21.3 risk of childhood acute lymphoblastic leukaemia is explained by a rare high-impact variant in CDKN2A. *Scientific Reports*, **2015**, 5, 15065	4.9	17
162	Age-related characteristics of cutaneous melanoma in a Spanish Mediterranean population. *International Journal of Dermatology*, **2015**, 54, 778-84	1.7	11
161	Mutations in TERT promoter and FGFR3 and telomere length in bladder cancer. *International Journal of Cancer*, **2015**, 137, 1621-9	7.5	65
160	RICTOR involvement in the PI3K/AKT pathway regulation in melanocytes and melanoma. *Oncotarget*, **2015**, 6, 28120-31	3.3	24
159	BRAF, NRAS and MC1R status in a prospective series of primary cutaneous melanoma. *British Journal of Dermatology*, **2015**, 172, 1128-31	4	14
158	TERT promoter mutations and telomere length in adult malignant gliomas and recurrences. *Oncotarget*, **2015**, 6, 10617-33	3.3	60
157	Frequent DPH3 promoter mutations in skin cancers. *Oncotarget*, **2015**, 6, 35922-30	3.3	42
156	A retrospective comparative exploratory study on two methylentetrahydrofolate reductase (MTHFR) polymorphisms in esophagogastric cancer: the A1298C MTHFR polymorphism is an independent prognostic factor only in neoadjuvantly treated gastric cancer patients. *BMC Cancer*, **2014**, 14, 58	4.8	15
155	Telomerase reverse transcriptase promoter mutations in primary cutaneous melanoma. *Nature Communications*, **2014**, 5, 3401	17.4	132
154	Genome-wide association study yields variants at 20p12.2 that associate with urinary bladder cancer. *Human Molecular Genetics*, **2014**, 23, 5545-57	5.6	29
153	Clinical Characteristics of Patients With Cutaneous Melanoma According to Variants in the Melanocortin 1 Receptor Gene. *Actas Dermo-sifiliográficas*, **2014**, 105, 159-171	0.5	
152	Inherited variability in a master regulator polymorphism (rs4846126) associates with survival in 5-FU treated colorectal cancer patients. *Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis*, **2014**, 766-767, 7-13	3.3	2
151	Germline sequence variants in TGM3 and RGS22 confer risk of basal cell carcinoma. *Human Molecular Genetics*, **2014**, 23, 3045-53	5.6	39
150	Polymorphisms in DNA repair genes XRCC1 and XRCC3, occupational exposure to arsenic and sunlight, and the risk of non-melanoma skin cancer in a European case-control study. *Environmental Research*, **2014**, 134, 382-9	7.9	6

149	Single-Nucleotide Polymorphisms Within the Thrombomodulin Gene (THBD) Predict Mortality in Patients With Graft-Versus-Host Disease. *Journal of Clinical Oncology*, **2014**, 32, 3421-7	2.2	36
148	Inherited variation in the PARP1 gene and survival from melanoma. *International Journal of Cancer*, **2014**, 135, 1625-33	7.5	22
147	An inherited variant in the gene coding for vitamin D-binding protein and survival from cutaneous melanoma: a BioGenoMEL study. *Pigment Cell and Melanoma Research*, **2014**, 27, 234-43	4.5	21
146	Early epigenetic downregulation of WNK2 kinase during pancreatic ductal adenocarcinoma development. *Oncogene*, **2014**, 33, 3401-10	9.2	24
145	TERT promoter mutations in cancer development. *Current Opinion in Genetics and Development*, **2014**, 24, 30-7	4.9	167
144	Clinical characteristics of patients with cutaneous melanoma according to variants in the melanocortin 1 receptor gene. *Actas Dermo-sifiliográficas*, **2014**, 105, 159-71	0.5	3
143	Variants at chromosome 20 (ASIP locus) and melanoma risk. *International Journal of Cancer*, **2013**, 132, 42-54	7.5	19
142	Distribution of MC1R variants among melanoma subtypes: p.R163Q is associated with lentigo maligna melanoma in a Mediterranean population. *British Journal of Dermatology*, **2013**, 169, 804-11	4	20
141	Variants at the 9p21 locus and melanoma risk. *BMC Cancer*, **2013**, 13, 325	4.8	23
140	Occupational exposure to arsenic and risk of nonmelanoma skin cancer in a multinational European study. *International Journal of Cancer*, **2013**, 133, 2182-91	7.5	35
139	TERT promoter mutations in familial and sporadic melanoma. *Science*, **2013**, 339, 959-61	33.3	1261
138	TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, 17426-31	11.5	236
137	Variation at 10p12.2 and 10p14 influences risk of childhood B-cell acute lymphoblastic leukemia and phenotype. *Blood*, **2013**, 122, 3298-307	2.2	119
136	Occupational exposure to ultraviolet radiation and risk of non-melanoma skin cancer in a multinational European study. *PLoS ONE*, **2013**, 8, e62359	3.7	40
135	Gene expression variations: potentialities of master regulator polymorphisms in colorectal cancer risk. *Mutagenesis*, **2012**, 27, 161-7	2.8	12
134	Functional, genetic, and epigenetic aspects of base and nucleotide excision repair in colorectal carcinomas. *Clinical Cancer Research*, **2012**, 18, 5878-87	12.9	59
133	Inherited variants in the MC1R gene and survival from cutaneous melanoma: a BioGenoMEL study. *Pigment Cell and Melanoma Research*, **2012**, 25, 384-94	4.5	50
132	Melanocortin-1 receptor, skin cancer and phenotypic characteristics (M-SKIP) project: study design and methods for pooling results of genetic epidemiological studies. *BMC Medical Research Methodology*, **2012**, 12, 116	4.7	10

131	Inorganic arsenic and basal cell carcinoma in areas of Hungary, Romania, and Slovakia: a case-control study. *Environmental Health Perspectives*, **2012**, 120, 721-6	8.4	77
130	Mutations and polymorphisms in TP53 gene--an overview on the role in colorectal cancer. *Mutagenesis*, **2012**, 27, 211-8	2.8	80
129	POMC and TP53 genetic variability and risk of basal cell carcinoma of skin: Interaction between host and genetic factors. *Journal of Dermatological Science*, **2011**, 63, 47-54	4.3	13
128	DNA repair gene and MTHFR gene polymorphisms as prognostic markers in locally advanced adenocarcinoma of the esophagus or stomach treated with cisplatin and 5-fluorouracil-based neoadjuvant chemotherapy. *Annals of Surgical Oncology*, **2011**, 18, 2688-98	3.1	46
127	A germline variant in the TP53 polyadenylation signal confers cancer susceptibility. *Nature Genetics*, **2011**, 43, 1098-103	36.3	203
126	Exposure to low environmental levels of benzene: evaluation of micronucleus frequencies and S-phenylmercapturic acid excretion in relation to polymorphisms in genes encoding metabolic enzymes. *Mutation Research - Genetic Toxicology and Environmental Mutagenesis*, **2011**, 719, 7-13	3	38
125	MTHFR and MTRR genotype and haplotype analysis and colorectal cancer susceptibility in a case-control study from the Czech Republic. *Mutation Research - Genetic Toxicology and Environmental Mutagenesis*, **2011**, 721, 74-80	3	40
124	Pancreatic cancer susceptibility loci and their role in survival. *PLoS ONE*, **2011**, 6, e27921	3.7	41
123	Familial bladder cancer and the related genes. *Current Opinion in Urology*, **2011**, 21, 386-92	2.8	14
122	Defining fast-growing melanomas: reappraisal of epidemiological, clinical, and histological features. *Melanoma Research*, **2011**, 21, 131-8	3.3	35
121	Rationale for an international consortium to study inherited genetic susceptibility to childhood acute lymphoblastic leukemia. *Haematologica*, **2011**, 96, 1049-54	6.6	32
120	5-Fluorouracil-based chemotherapy for colorectal cancer and MTHFR/MTRR genotypes. *British Journal of Clinical Pharmacology*, **2011**, 72, 162-3	3.8	52
119	European genome-wide association study identifies SLC14A1 as a new urinary bladder cancer susceptibility gene. *Human Molecular Genetics*, **2011**, 20, 4268-81	5.6	105
118	DNA damage, DNA repair rates and mRNA expression levels of cell cycle genes (TP53, p21(CDKN1A), BCL2 and BAX) with respect to occupational exposure to styrene. *Carcinogenesis*, **2011**, 32, 74-9	4.6	5
117	Interaction between functional polymorphic variants in cytokine genes, established risk factors and susceptibility to basal cell carcinoma of skin. *Carcinogenesis*, **2011**, 32, 1849-54	4.6	16
116	Epigenetic deregulation of TCF21 inhibits metastasis suppressor KISS1 in metastatic melanoma. *Carcinogenesis*, **2011**, 32, 1467-73	4.6	54
115	ERCC5 p.Asp1104His and ERCC2 p.Lys751Gln polymorphisms are independent prognostic factors for the clinical course of melanoma. *Journal of Investigative Dermatology*, **2011**, 131, 1280-90	4.3	23
114	A sequence variant at 4p16.3 confers susceptibility to urinary bladder cancer. *Nature Genetics*, **2010**, 42, 415-9	36.3	138

113	Variation in CDKN2A at 9p21.3 influences childhood acute lymphoblastic leukemia risk. *Nature Genetics*, **2010**, 42, 492-4	36.3	214
112	A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. *Nature Genetics*, **2010**, 42, 978-84	36.3	408
111	Association between the germline MC1R variants and somatic BRAF/NRAS mutations in melanoma tumors. *Journal of Investigative Dermatology*, **2010**, 130, 2844-8	4.3	25
110	Single-nucleotide polymorphisms in DNA-repair genes and cutaneous melanoma. *Mutation Research - Genetic Toxicology and Environmental Mutagenesis*, **2010**, 702, 8-16	3	26
109	Verification of the susceptibility loci on 7p12.2, 10q21.2, and 14q11.2 in precursor B-cell acute lymphoblastic leukemia of childhood. *Blood*, **2010**, 115, 1765-7	2.2	107
108	Lifetime exposure to arsenic in residential drinking water in Central Europe. *International Archives of Occupational and Environmental Health*, **2010**, 83, 471-81	3.2	23
107	Genotypes, haplotypes and diplotypes of three XPC polymorphisms in urinary-bladder cancer patients. *Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis*, **2010**, 694, 39-44	3.3	16
106	Genetics of pigmentation in skin cancer--a review. *Mutation Research - Reviews in Mutation Research* , **2010**, 705, 141-153	7	121
105	Modulation of DNA repair capacity and mRNA expression levels of XRCC1, hOGG1 and XPC genes in styrene-exposed workers. *Toxicology and Applied Pharmacology*, **2010**, 248, 194-200	4.6	22
104	Somatic alterations in the melanoma genome: a high-resolution array-based comparative genomic hybridization study. *Genes Chromosomes and Cancer*, **2010**, 49, 733-45	5	79
103	XPC 939 and XRCC3 Polymorphismen sind Prognosefaktoren bei lokal fortgeschrittenen Adenokarzinomen des oberen Gastrointestinaltraktes nach neoadjuvanter 5-FU und Cisplatin basierter Chemotherapie. *Langenbecks Archiv Fu r Chirurgie Supplement*, **2009**, 99-101		
102	Polymorphisms in DNA repair genes, smoking, and bladder cancer risk: findings from the international consortium of bladder cancer. *Cancer Research*, **2009**, 69, 6857-64	10.1	94
101	Single nucleotide polymorphisms in DNA repair genes XRCC1 and APEX1 in progression and survival of primary cutaneous melanoma patients. *Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis*, **2009**, 661, 78-84	3.3	21
100	Genotype and haplotype analysis of cell cycle genes in sporadic colorectal cancer in the Czech Republic. *Human Mutation*, **2009**, 30, 661-8	4.7	41
99	Melanocortin receptor 1 variants and melanoma risk: a study of 2 European populations. *International Journal of Cancer*, **2009**, 125, 1868-75	7.5	56
98	A case-control study of childhood acute lymphoblastic leukaemia and polymorphisms in the TGF-beta and receptor genes. *Pediatric Blood and Cancer*, **2009**, 52, 819-23	3	8
97	Sequence variants at the TERT-CLPTM1L locus associate with many cancer types. *Nature Genetics*, **2009**, 41, 221-7	36.3	509
96	Genome-wide association study identifies five susceptibility loci for glioma. *Nature Genetics*, **2009**, 41, 899-904	36.3	640

95	New common variants affecting susceptibility to basal cell carcinoma. *Nature Genetics*, **2009**, 41, 909-14	36.3	275
94	Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer. *Nature Genetics*, **2009**, 41, 991-5	36.3	270
93	Malignant Melanoma: Genetic Overview. *Actas Dermo-sifiliográficas*, **2009**, 100, 38-51	0.5	12
92	Malignant melanoma--a genetic overview. *Actas Dermo-sifiliográficas*, **2009**, 100 Suppl 1, 38-51	0.5	5
91	ASIP and TYR pigmentation variants associate with cutaneous melanoma and basal cell carcinoma. *Nature Genetics*, **2008**, 40, 886-91	36.3	265
90	Sequence variant on 8q24 confers susceptibility to urinary bladder cancer. *Nature Genetics*, **2008**, 40, 1307-12	36.3	332
89	Common variants on 1p36 and 1q42 are associated with cutaneous basal cell carcinoma but not with melanoma or pigmentation traits. *Nature Genetics*, **2008**, 40, 1313-8	36.3	93
88	Inherited susceptibility to bleomycin-induced micronuclei: correlating polymorphisms in GSTT1, GSTM1 and DNA repair genes with mutagen sensitivity. *Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis*, **2008**, 638, 90-7	3.3	23
87	DNA repair genetic polymorphisms and risk of colorectal cancer in the Czech Republic. *Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis*, **2008**, 638, 146-53	3.3	95
86	Mutation analysis of the EGFR-NRAS-BRAF pathway in melanomas from black Africans and other subgroups of cutaneous melanoma. *Melanoma Research*, **2008**, 18, 29-35	3.3	66
85	MC1R variants associated susceptibility to basal cell carcinoma of skin: interaction with host factors and XRCC3 polymorphism. *International Journal of Cancer*, **2008**, 122, 1787-93	7.5	49
84	Three novel mutations of the EDA gene in Chinese patients with X-linked hypohidrotic ectodermal dysplasia. *British Journal of Dermatology*, **2008**, 158, 614-7	4	2
83	Influence of DNA repair gene polymorphisms on the initial repair of MMS-induced DNA damage in human lymphocytes as measured by the alkaline comet assay. *Environmental and Molecular Mutagenesis*, **2008**, 49, 669-75	3.2	7
82	B-RAF and N-RAS mutations are preserved during short time in vitro propagation and differentially impact prognosis. *PLoS ONE*, **2007**, 2, e236	3.7	107
81	Metabolism of low-dose inorganic arsenic in a central European population: influence of sex and genetic polymorphisms. *Environmental Health Perspectives*, **2007**, 115, 1081-6	8.4	169
80	Differential gene expression in melanocytic nevi with the V600E BRAF mutation. *Genes Chromosomes and Cancer*, **2007**, 46, 1019-27	5	16
79	Folate metabolic gene polymorphisms and childhood acute lymphoblastic leukemia: a case-control study. *Leukemia*, **2007**, 21, 320-5	10.7	59
78	No association between MDM2 SNP309 promoter polymorphism and basal cell carcinoma of the skin. *British Journal of Dermatology*, **2007**, 157, 375-7	4	21

77	Association of DNA repair polymorphisms with DNA repair functional outcomes in healthy human subjects. *Carcinogenesis*, **2007**, 28, 657-64	4.6	147
76	Polymorphisms in XPD, XPC and the risk of death in patients with urinary bladder neoplasms. *Acta Oncologica*, **2007**, 46, 31-41	3.2	31
75	Multiple melanomas after treatment for Hodgkin lymphoma in a non-Dutch p16-Leiden mutation carrier with 2 MC1R high-risk variants. *Archives of Dermatology*, **2007**, 143, 495-9		7
74	ARLTS1 polymorphisms and basal cell carcinoma of the skin. *Hereditary Cancer in Clinical Practice*, **2007**, 5, 25-9	2.3	1
73	Polymorphisms in NQO1 and the clinical course of urinary bladder neoplasms. *Scandinavian Journal of Urology and Nephrology*, **2007**, 41, 182-90		14
72	Genetic polymorphisms and possible gene-gene interactions in metabolic and DNA repair genes: effects on DNA damage. *Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis*, **2006**, 593, 22-31	3.3	29
71	Ala228 variant of trail receptor 1 affecting the ligand binding site is associated with chronic lymphocytic leukemia, mantle cell lymphoma, prostate cancer, head and neck squamous cell carcinoma and bladder cancer. *International Journal of Cancer*, **2006**, 118, 1831-5	7.5	37
70	ARLTS1 variants and melanoma risk. *International Journal of Cancer*, **2006**, 119, 1736-7	7.5	21
69	The XPD 751Gln allele is associated with an increased risk for esophageal adenocarcinoma: a population-based case-control study in Sweden. *Carcinogenesis*, **2006**, 27, 1835-41	4.6	68
68	Prognostic significance of homozygous deletions and multiple duplications at the CDKN2A (p16INK4a)/ARF (p14ARF) locus in urinary bladder cancer. *Scandinavian Journal of Urology and Nephrology*, **2006**, 40, 363-9		12
67	Arsenic exposure in Hungary, Romania and Slovakia. *Journal of Environmental Monitoring*, **2006**, 8, 203-8		94
66	Influence of polymorphism in DNA repair and defence genes on p53 mutations in bladder tumours. *Cancer Letters*, **2006**, 241, 142-9	9.9	43
65	Differences in global gene expression in melanoma cell lines with and without homozygous deletion of the CDKN2A locus genes. *Melanoma Research*, **2006**, 16, 297-307	3.3	16
64	A single-nucleotide polymorphism in the XPG gene, and tumour stage, grade, and clinical course in patients with nonmuscle-invasive neoplasms of the urinary bladder. *BJU International*, **2006**, 97, 847-51	5.6	18
63	Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. *Pigment Cell & Melanoma Research*, **2006**, 19, 290-302		378
62	Case-control study in basal cell carcinoma of the skin: single nucleotide polymorphisms in three interleukin promoters pre-analysed in pooled DNA. *British Journal of Dermatology*, **2006**, 155, 1139-44	4	21
61	Single nucleotide polymorphisms in DNA repair genes and basal cell carcinoma of skin. *Carcinogenesis*, **2006**, 27, 1676-81	4.6	70
60	MTHFR genetic polymorphisms and susceptibility to childhood acute lymphoblastic leukemia. *Blood* , **2005**, 106, 2590-1; author reply 2591-2	2.2	44

59	Mutations in the BRAF and N-ras genes in childhood acute lymphoblastic leukaemia. *Leukemia*, **2005**, 19, 310-2	10.7	40
58	BRAF and NRAS mutations are frequent in nodular melanoma but are not associated with tumor cell proliferation or patient survival. *Journal of Investigative Dermatology*, **2005**, 125, 312-7	4.3	93
57	DNA repair and cyclin D1 polymorphisms and styrene-induced genotoxicity and immunotoxicity. *Toxicology and Applied Pharmacology*, **2005**, 207, 302-9	4.6	12
56	Micronuclei in humans induced by exposure to low level of ionizing radiation: influence of polymorphisms in DNA repair genes. *Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis*, **2005**, 570, 105-17	3.3	80
55	Basal cell carcinoma and variants in genes coding for immune response, DNA repair, folate and iron metabolism. *Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis*, **2005**, 574, 105-11	3.3	54
54	B-RAF mutations in tumors from melanoma-breast cancer families. *International Journal of Cancer*, **2005**, 113, 336-7	7.5	2
53	Influence of GSTM1, GSTT1, GSTP1 and NAT2 genotypes on the p53 mutational spectrum in bladder tumours. *International Journal of Cancer*, **2005**, 113, 761-8	7.5	20
52	Low frequency of BRAF and CDKN2A mutations in endometrial cancer. *International Journal of Cancer*, **2005**, 115, 930-4	7.5	41
51	Determination of allele frequency in pooled DNA: comparison of three PCR-based methods. *BioTechniques*, **2005**, 39, 853-8	2.5	35
50	Effect of common B-RAF and N-RAS mutations on global gene expression in melanoma cell lines. *Carcinogenesis*, **2005**, 26, 1224-32	4.6	118
49	Cytogenetic markers, DNA single-strand breaks, urinary metabolites, and DNA repair rates in styrene-exposed lamination workers. *Environmental Health Perspectives*, **2004**, 112, 867-71	8.4	65
48	BRAF mutations are common somatic events in melanocytic nevi. *Journal of Investigative Dermatology*, **2004**, 122, 342-8	4.3	171
47	Markers of individual susceptibility and DNA repair rate in workers exposed to xenobiotics in a tire plant. *Environmental and Molecular Mutagenesis*, **2004**, 44, 283-92	3.2	70
46	Polymorphisms in DNA repair and metabolic genes in bladder cancer. *Carcinogenesis*, **2004**, 25, 729-34	4.6	257
45	Genetic polymorphisms in DNA repair genes and possible links with DNA repair rates, chromosomal aberrations and single-strand breaks in DNA. *Carcinogenesis*, **2004**, 25, 757-63	4.6	198
44	Single nucleotide polymorphisms in breast cancer. *Oncology Reports*, **2004**, 11, 917	3.5	22
43	Single nucleotide polymorphisms in breast cancer. *Oncology Reports*, **2004**, 11, 917-22	3.5	113
42	Simultaneous detection of the exon 10 polymorphism and a novel intronic single base insertion polymorphism in the XPD gene using single strand conformation polymorphism. *Mutagenesis*, **2003**, 18, 207-9	2.8	5

41	Clinical course of bladder neoplasms and single nucleotide polymorphisms in the CDKN2A gene. *International Journal of Cancer*, **2003**, 104, 98-103	7.5	29
40	Activating BRAF and N-Ras mutations in sporadic primary melanomas: an inverse association with allelic loss on chromosome 9. *Oncogene*, **2003**, 22, 9217-24	9.2	81
39	Single nucleotide polymorphisms in the XPG gene: determination of role in DNA repair and breast cancer risk. *International Journal of Cancer*, **2003**, 103, 671-5	7.5	68
38	Detecting homozygous deletions in the CDKN2A(p16(INK4a))/ARF(p14(ARF)) gene in urinary bladder cancer using real-time quantitative PCR. *Clinical Cancer Research*, **2003**, 9, 235-42	12.9	78
37	BRAF mutations in metastatic melanoma: a possible association with clinical outcome. *Clinical Cancer Research*, **2003**, 9, 3362-8	12.9	142
36	Genetic status of cell cycle regulators in squamous cell carcinoma of the oesophagus: the CDKN2A (p16(INK4a) and p14(ARF)) and p53 genes are major targets for inactivation. *Carcinogenesis*, **2002**, 23, 645-55	4.6	52
35	Significant impact of promoter hypermethylation and the 540 C>T polymorphism of CDKN2A in cutaneous melanoma of the vertical growth phase. *American Journal of Pathology*, **2002**, 161, 229-37	5.8	81
34	A single nucleotide polymorphism in the 3Runtranslated region of the CDKN2A gene is common in sporadic primary melanomas but mutations in the CDKN2B, CDKN2C, CDK4 and p53 genes are rare. *International Journal of Cancer*, **2001**, 95, 388-93	7.5	81
33	Ethnic variation in genotype frequencies of a p53 intron 7 polymorphism. *Mutagenesis*, **2001**, 16, 475-8	2.8	11
32	Polymorphic insertion of additional repeat within an area of direct 8 bp tandem repeats in the 5Runtranslated region of the p53R2 gene and cancer risk. *Mutagenesis*, **2001**, 16, 547-50	2.8	4
31	Increased frequency of LOH on chromosome 9 in sporadic primary melanomas is associated with increased patient age at diagnosis. *Mutagenesis*, **2000**, 15, 257-60	2.8	6
30	Single nucleotide polymorphism analyses of the human proliferating cell nuclear antigen (pCNA) and flap endonuclease (FEN1) genes. *International Journal of Cancer*, **2000**, 88, 938-42	7.5	16
29	Analysis of G(1)/S checkpoint regulators in metastatic melanoma. *Genes Chromosomes and Cancer*, **2000**, 28, 404-14	5	67
28	Detection of methylation damage in DNA of gastric cancer tissues using 32P postlabelling assay. *Japanese Journal of Cancer Research*, **1999**, 90, 1104-8		1
27	Comparison of (32)P-postlabeling and high-resolution GC/MS in quantifying N7-(2-Hydroxyethyl)guanine adducts. *Chemical Research in Toxicology*, **1999**, 12, 979-84	4	16
26	Loss of heterozygosity at chromosome 9p21 (INK4-p14ARF locus): homozygous deletions and mutations in the p16 and p14ARF genes in sporadic primary melanomas. *Melanoma Research*, **1999**, 9, 138-47	3.3	44
25	Mutations in the CDKN2A (p16INK4a) gene in microdissected sporadic primary melanomas. *International Journal of Cancer*, **1998**, 75, 193-8	7.5	41
24	Selective deletion of exon 1 beta of the p19ARF gene in metastatic melanoma cell lines. *Genes Chromosomes and Cancer*, **1998**, 23, 273-7	5	53

23	Mutations in the CDKN2A (p16INK4a) gene in microdissected sporadic primary melanomas **1998**, 75, 193		1
22	32P-postlabelling analysis of isomeric 7-alkylguanine adducts of styrene oxide. *Carcinogenesis*, **1997**, 18, 407-14	4.6	15
21	Persistence of 7-(2-hydroxyethyl) guanine-DNA adducts in rats exposed to ethene by inhalation. *Biomarkers*, **1997**, 2, 355-60	2.6	12
20	7-Alkylguanine adducts of styrene oxide determined by 32P-postlabeling in DNA and human embryonal lung fibroblasts (HEL). *Carcinogenesis*, **1996**, 17, 801-8	4.6	30
19	Future Research Directions in the Use of Biomarkers. *Environmental Health Perspectives*, **1996**, 104, 459	8.4	1
18	Future research directions in the use of biomarkers. *Environmental Health Perspectives*, **1996**, 104 Suppl 3, 459-64	8.4	4
17	32P-postlabelling of diastereomeric 7-alkylguanine adducts of butadiene monoepoxide. *Carcinogenesis*, **1996**, 17, 1297-303	4.6	7
16	Separation of 7-methyl- and 7-(2-hydroxyethyl)-guanine adducts in human DNA samples using a combination of TLC and HPLC. *Carcinogenesis*, **1996**, 17, 485-92	4.6	34
15	Separation of transforming amino acid-substituting mutations in codons 12, 13 and 61 the N-ras gene by constant denaturant capillary electrophoresis (CDCE). *Carcinogenesis*, **1995**, 16, 2667-73	4.6	26
14	Analysis of UV-induced DNA photoproducts by 32P-postlabelling. *Carcinogenesis*, **1995**, 16, 113-8	4.6	36
13	32P-postlabelling method for the detection of 7-alkylguanine adducts formed by the reaction of different 1,2-alkyl epoxides with DNA. *Carcinogenesis*, **1995**, 16, 483-9	4.6	35
12	Uptake, distribution, and formation of hemoglobin and DNA adducts after inhalation of C2-C8 1-alkenes (olefins) in the rat. *Carcinogenesis*, **1995**, 16, 1603-9	4.6	40
11	N-nitrosodimethylamine and 7-methylguanine DNA adducts in tissues of rats fed Chinese salted fish. *Cancer Letters*, **1995**, 94, 85-90	9.9	9
10	Caffeine-derived N-nitroso compounds. II. Synthesis and characterization of nitrosation products from caffeidine and caffeidine acid. *Chemical Research in Toxicology*, **1993**, 6, 50-8	4	9
9	Caffeine-derived N-nitroso compounds. III: Mutagenicity in S. typhimurium and in vitro induction of DNA single-strand breaks in rat hepatocytes by mononitrosocaffeidine and dinitrosocaffeidine. *Mutation Research - Environmental Mutagenesis and Related Subjects Including Methodology*, **1993**, 292, 41-9		5
8	Caffeine-derived N-nitroso compounds--I: Nitrosatable precursors from caffeine and their potential relevance in the etiology of oesophageal and gastric cancers in Kashmir, India. *Carcinogenesis*, **1992**, 13, 2179-82	4.6	26
7	Increased exposure to dietary amines and nitrate in a population at high risk of oesophageal and gastric cancer in Kashmir (India). *Carcinogenesis*, **1992**, 13, 1331-5	4.6	72
6	Salivary nitrate and nitrite concentrations from a sample population of children and adults in high risk area for esophageal and gastric cancers in Kashmir, India. *Cancer Letters*, **1992**, 64, 133-6	9.9	10

5	Effect of dietary nitrate on endogenous nitrosation of piperazine in humans. *Cancer Letters*, **1992**, 65, 139-43	9.9	8
4	Endogenous formation of N-nitrosamines from piperazine and their urinary excretion following antihelmintic treatment with piperazine citrate. *Carcinogenesis*, **1991**, 12, 1595-9	4.6	11
3	N-nitroso compounds and their precursors in Brassica oleracea. *Cancer Letters*, **1990**, 54, 61-5	9.9	23
2	Telomere length, arsenic exposure and risk of basal cell carcinoma of skin		2
1	Assessment of Polygenic Architecture and Risk Prediction based on Common Variants Across Fourteen Cancers		1